113 related articles for article (PubMed ID: 19937842)
1. RNA-interference approach to study functions of NADPH : cytochrome P450 oxidoreductase in human hepatocytes.
Feidt DM; Klein K; Nüssler A; Zanger UM
Chem Biodivers; 2009 Nov; 6(11):2084-91. PubMed ID: 19937842
[TBL] [Abstract][Full Text] [Related]
2. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
Flück CE; Nicolo C; Pandey AV
Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
[TBL] [Abstract][Full Text] [Related]
3. P450 oxidoreductase expressed in rat chondrocytes modulates chondrogenesis via cholesterol- and Indian Hedgehog-dependent mechanisms.
Aguilar A; Wu S; De Luca F
Endocrinology; 2009 Jun; 150(6):2732-9. PubMed ID: 19264869
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells.
Westerink WM; Schoonen WG
Toxicol In Vitro; 2007 Dec; 21(8):1581-91. PubMed ID: 17637504
[TBL] [Abstract][Full Text] [Related]
5. Biochemical analysis of mutations in P450 oxidoreductase.
Pandey AV
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1186-91. PubMed ID: 17073782
[TBL] [Abstract][Full Text] [Related]
6. Effect of genetic variation on human cytochrome p450 reductase-mediated paraquat cytotoxicity.
Han JF; Wang SL; He XY; Liu CY; Hong JY
Toxicol Sci; 2006 May; 91(1):42-8. PubMed ID: 16495354
[TBL] [Abstract][Full Text] [Related]
7. The effect of dimethyl sulfoxide on the function of cytochrome P450 2D6 in HepG2 cells upon the co-expression with NADPH-cytochrome P450 reductase.
Narimatsu S; Takatsu N; Yamano S; Inoue Y; Hanioka N; Kiryu K; Naito S; Gonzalez FJ; Yamamoto S
Chem Biol Interact; 2006 Jan; 159(1):47-57. PubMed ID: 16214121
[TBL] [Abstract][Full Text] [Related]
8. Stable expression of human cytochrome P450 3A4 in conjunction with human NADPH-cytochrome P450 oxidoreductase in V79 Chinese hamster cells.
Schneider A; Schmalix WA; Siruguri V; de Groene EM; Horbach GJ; Kleingeist B; Lang D; Böcker R; Belloc C; Beaune P; Greim H; Doehmer J
Arch Biochem Biophys; 1996 Aug; 332(2):295-304. PubMed ID: 8806738
[TBL] [Abstract][Full Text] [Related]
9. Stable expression and coexpression of human cytochrome P450 oxidoreductase and cytochrome P450 1A2 in V79 Chinese hamster cells: sensitivity to quinones and biotransformation of 7-alkoxyresorufins and triazines.
Schmalix WA; Lang D; Schneider A; Bocker R; Greim H; Doehmer J
Drug Metab Dispos; 1996 Dec; 24(12):1314-9. PubMed ID: 8971136
[TBL] [Abstract][Full Text] [Related]
10. Modeling of human P450 oxidoreductase structure by in silico mutagenesis and MD simulation.
Flück CE; Mullis PE; Pandey AV
Mol Cell Endocrinol; 2009 Dec; 313(1-2):17-22. PubMed ID: 19744540
[TBL] [Abstract][Full Text] [Related]
11. Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells.
Heintze T; Klein K; Hofmann U; Zanger UM
Sci Rep; 2021 Jan; 11(1):1000. PubMed ID: 33441761
[TBL] [Abstract][Full Text] [Related]
12. Optimization of heme precursors for the expression of human cytochrome P450 2A13 and its co-expression with oxidoreductase in baculovirus/sf9 system.
Lu HY; Qiu LL; Yang XJ; Zhang XM; Zhang Z; Wang SL
J Biochem; 2013 Jun; 153(6):555-63. PubMed ID: 23463547
[TBL] [Abstract][Full Text] [Related]
13. NADPH-cytochrome P450 oxidoreductase from the chicken (Gallus gallus): sequence characterization, functional expression and kinetic study.
Zhou X; Li M; Sheng C; Qiu X
Comp Biochem Physiol C Toxicol Pharmacol; 2011 Jan; 153(1):53-9. PubMed ID: 20728568
[TBL] [Abstract][Full Text] [Related]
14. Examination of Zolpidem effects on AhR- and PXR-dependent expression of drug-metabolizing cytochromes P450 in primary cultures of human hepatocytes.
Bachleda P; Vrzal R; Pivnicka J; Cvek B; Dvorak Z
Toxicol Lett; 2009 Dec; 191(1):74-8. PubMed ID: 19686824
[TBL] [Abstract][Full Text] [Related]
15. NADPH-cytochrome P450 reductase expression and enzymatic activity in primary-like human hepatocytes and HepG2 cells for in vitro biotransformation studies.
Schulz C; Kammerer S; Küpper JH
Clin Hemorheol Microcirc; 2019; 73(1):249-260. PubMed ID: 31561354
[TBL] [Abstract][Full Text] [Related]
16. The disruption of hepatic cytochrome p450 reductase alters mouse lipid metabolism.
Mutch DM; Klocke B; Morrison P; Murray CA; Henderson CJ; Seifert M; Williamson G
J Proteome Res; 2007 Oct; 6(10):3976-84. PubMed ID: 17722906
[TBL] [Abstract][Full Text] [Related]
17. Expression, purification, and characterization of a catalytically active human cytochrome P450 1A2:rat NADPH-cytochrome P450 reductase fusion protein.
Parikh A; Guengerich FP
Protein Expr Purif; 1997 Apr; 9(3):346-54. PubMed ID: 9126606
[TBL] [Abstract][Full Text] [Related]
18. [Antley-Bixler syndrome or POR deficiency?].
Tomková M; Marohnic CC; Baxová A; Martásek P
Cas Lek Cesk; 2008; 147(5):261-5. PubMed ID: 18630181
[TBL] [Abstract][Full Text] [Related]
19. MiR-214 promotes the alcohol-induced oxidative stress via down-regulation of glutathione reductase and cytochrome P450 oxidoreductase in liver cells.
Dong X; Liu H; Chen F; Li D; Zhao Y
Alcohol Clin Exp Res; 2014 Jan; 38(1):68-77. PubMed ID: 23905773
[TBL] [Abstract][Full Text] [Related]
20. P450 oxidoreductase: genotyping, expression, purification of recombinant protein, and activity assessments of wild-type and mutant protein.
Agrawal V; Miller WL
Methods Mol Biol; 2013; 987():225-37. PubMed ID: 23475681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
